82 results on '"Pacheco-Figueiredo, L"'
Search Results
2. Clinical Validation and Performance Assessment of a TERT/FGFR3/KRAS Mutation screening urinary biomarker test for recurrence surveillance in non-muscle invasive bladder cancer
3. Uromonitor®: Clinical validation and performance assessment of a urinary biomarker for recurrence in non-muscle invasive bladder cancer patients
4. Uromonitor-V2®: Clinical Validation and Performance Assessment of a Urinary Biomarker for Recurrence in Non-Muscle Invasive Bladder Cancer Patients
5. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
6. Cumulative incidence and predictive factors of radiation cystitis in patients with localized prostate cancer
7. Prognostic impact of variant histology in bladder cancer: Would early and aggressive treatment shift the paradigm?
8. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium
9. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer
10. Androgen deprivation therapy and cognitive decline in the NEON-PC study
11. P245 - Uromonitor-V2®: Clinical Validation and Performance Assessment of a Urinary Biomarker for Recurrence in Non-Muscle Invasive Bladder Cancer Patients
12. The impact of female urinary incontinence on mental health disease - a population-based study
13. Kidney transplantation from Donation after Cardiocirculatory Death (DCD) after Extracorporeal Membrane Oxygenation (ECMO) – What can we say after 5 years of experience?
14. Benefits and harms of Botulinum Toxin-A in the treatment of chronic pelvic pain syndromes: Systematic review by the EAU Chronic Pelvic Pain Panel
15. Prevalence of urinary incontinence in portuguese women, associated comorbidities and use of healthcare resources - a population-based study
16. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
17. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees
18. Endothelial function in patients with metabolic syndrome and erectile dysfunction: a question of Angiopoietin imbalance?
19. Kidney transplantation from donation after cardiocirculatory death (DCD) after extracorporeal membrane oxygenation (ECMO) – outcomes from a longitudinal assessment with three years of experience
20. EO6 - Prognostic impact of variant histology in bladder cancer: Would early and aggressive treatment shift the paradigm?
21. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
22. PIONEER’s update and integration of a localised prostate cancer core outcome set for effectiveness trials and a standard set for clinical practice
23. Renal cell carcinoma with venous thrombus in metastatic patients at diagnosis, should surgery be offered?
24. La incidencia acumulada y los factores predictivos de la cistitis rádica en pacientes con cáncer de próstata localizado
25. Kidney transplantation from non-heart-beating donors (NHBD) after extracorporeal membranous oxygenation (ECMO) – initial experience and comparison to brain-dead donors (BDD) outcomes
26. Gleason 6 (3+3) prostate cancer: What have we done and what are we doing?
27. Main determinants of the extent of lymphadenectomy in radical cystectomy: A study based on clinical practice
28. Small intestinal submucosa graft in the treatment of Peyronie’s disease: Long term patient-reported outcomes and satisfaction
29. PT342 - PIONEER’s update and integration of a localised prostate cancer core outcome set for effectiveness trials and a standard set for clinical practice
30. 661 - Kidney transplantation from non-heart-beating donors (NHBD) after extracorporeal membranous oxygenation (ECMO) – initial experience and comparison to brain-dead donors (BDD) outcomes
31. Metabolic syndrome and erectile dysfunction: Assessing the clinical and hemodynamic parameters
32. P146 - Main determinants of the extent of lymphadenectomy in radical cystectomy: A study based on clinical practice
33. P029 - Gleason 6 (3+3) prostate cancer: What have we done and what are we doing?
34. 374 - Small intestinal submucosa graft in the treatment of Peyronie’s disease: Long term patient-reported outcomes and satisfaction
35. 210 Endothelial function in patients with metabolic syndrome and erectile dysfunction: A question of Angiopoietin imbalance?
36. P098 - Renal cell carcinoma with venous thrombus in metastatic patients at diagnosis, should surgery be offered?
37. Association of TP53 codon 72 polymorphism with glioma tumor risk
38. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort
39. A0359 - Clinical Validation and Performance Assessment of a TERT/FGFR3/KRAS Mutation screening urinary biomarker test for recurrence surveillance in non-muscle invasive bladder cancer.
40. A1251 - Low-Intensity Extracorporeal Shock Wave Treatment (LI-ESWT) efficacy treating a cohort of real-life patients with erectile dysfunction.
41. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
42. Real-life Data on First- and Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer With Abiraterone, Enzalutamide and Cabazitaxel - A multicentric Study From Portugal.
43. Prognostic impact of variant histology in bladder cancer: Would early and aggressive treatment shift the paradigm?
44. Association between sociodemographic and clinical features, health behaviors, and health literacy of patients with prostate cancer and prostate cancer prognostic stage.
45. Self-reported urinary incontinence in women is higher with increased age, lower educational level, lower income, number of comorbidities, and impairment of mental health. Results of a large, population-based, national survey in Portugal.
46. Prostate cancer treatment in Portugal: a nationwide analysis.
47. Anxiety and Depression in Patients with Prostate Cancer, at Cancer Diagnosis and after a One-Year Follow-Up.
48. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium.
49. Prevalence of Cognitive Impairment before Prostate Cancer Treatment.
50. The Benefits and Harms of Botulinum Toxin-A in the Treatment of Chronic Pelvic Pain Syndromes: A Systematic Review by the European Association of Urology Chronic Pelvic Pain Panel.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.